Paz Soldan M Mateo, Rodriguez Moses
Program in Molecular Neuroscience, Mayo Medical and Graduate Schools, 200 First Street SW, Rochester, MN 55905, USA.
J Infect Dis. 2002 Dec 1;186 Suppl 2:S248-53. doi: 10.1086/344283.
Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients-but a combination of therapeutic approaches may be required in practice.
在中枢神经系统（CNS）的原发性脱髓鞘疾病如多发性硬化症（MS）中，促进髓鞘修复仍然是一个重要的治疗目标。MS病灶内病理学的新出现的异质性，尤其是少突胶质细胞的不同存活率，表明治疗策略可能需要根据个体患者的需求进行调整。已经提出了多种治疗策略来促进中枢神经系统的髓鞘修复：细胞移植、生长因子治疗和抗体治疗，但每种提出的治疗方法在脱髓鞘的发病机制方面都有不同的影响。其中，抗体治疗最适合立即应用于患者——但在实践中可能需要联合治疗方法。
